We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellectricon Presents Transfection Solutions for Drug Discovery at Experimental Biology 2013
Product News

Cellectricon Presents Transfection Solutions for Drug Discovery at Experimental Biology 2013

Cellectricon Presents Transfection Solutions for Drug Discovery at Experimental Biology 2013
Product News

Cellectricon Presents Transfection Solutions for Drug Discovery at Experimental Biology 2013


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cellectricon Presents Transfection Solutions for Drug Discovery at Experimental Biology 2013"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellectricon will be exhibiting its revolutionary in-situ transfection technology platforms on booth #1178 at the Experimental Biology conference (20-24 April, Boston, US).

Cellectricon will also present two posters on April 24, focusing on high performance in-situ transfection.

The poster “Transfection of primary and iPSC-derived cells by capillary electroporation” (LB162) explores how Cellectricon’s novel electroporation Cellaxess® ACE system is ideal for in-situ transfection of any adherent cell type.

Minimal cell processing and low voltages ensure excellent viability and completely retained morphology, in any cell culture format.

For in-situ transfection applications on a larger scale, the poster “High throughput in-situ transfection of primary and iPSC-derived cells” (LB163) details how the novel electroporation platform Cellaxess® Elektra is optimized for in-vitro transfection of primary and iPSC-derived cells, directly into 384-well plates.

With virtually no impact on cell viability or morphology, this system is ideal for screening applications such as cDNA and RNAi.

The presentations will commence from 12:15 to 13:30, and posters will be available for viewing throughout the day.

Advertisement